In Re Glumetza Antitrust Litigation
Opinion
Trial Court Opinion
UNITED STATES DISTRICT COURT
NORTHERN DISTRICT OF CALIFORNIA
In re No. C 19-05822 WHA GLUMETZA ANTITRUST No. C 19-06138 WHA LITIGATION. No. C 19-06839 WHA No. C 19-07843 WHA No. C 19-08155 WHA No. C 20-01198 WHA This Document Relates to: No. C 20-05251 WHA 14 ALL ACTIONS. (Consolidated)
ORDER RE SUMMARY
JUDGMENT
17 INTRODUCTION In a secret pharmaceutical-patent infringement settlement agreement, concealed from the district judge, brand and generic manufacturers of the type 2 diabetes drug Glumetza allegedly pledged not to compete with each other by agreeing to not introduce a generic version of the drug for several years. So, while generic competition should have driven drug prices down, the brand manufacturer instead hiked prices up. The generic manufacturer belatedly entered the market at premium pricing, and, as a result, the conspiring manufacturers allegedly…